Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy
Year: 2025
Type: article
Study design: Case Report
Abstract: Meningiomas are the most common primary tumor in the central nervous system, yet an effective systemic treatment remains a challenge. We present a grade 2 meningioma that resulted in a positive and prolonged response to pembrolizumab. Our case had polybromo-1 ( PBRM1 ) and BAP1 functional loss, tumor mutational burden of 4 Muts/Mb, stable microsatellite status, and a PD-L1 tumor proportion score of <1%. We add to the limited literature regarding PBRM1 mutations in meningiomas. We discuss our findings in relation to the ongoing investigation of immune checkpoint inhibitor therapy in treating higher-grade refractory meningiomas.
Source: Frontiers in Oncology
Authors: Ellen Reusch, Keng Hee Peh, Rachael Morgan, Harry Momo, David Orren, Stephanie Rock, Thomas Pittman, Janna Neltner, Jill Kolesar, John Villano
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Award: G6888208216
OpenAlex ID: W4415408288